Global Obesity Drugs Market valued at $2.3 billion (2022), is poised to witness a 25% CAGR by 2027

BRUSSELS - Feb. 8, 2023 - PRLog -- Obesity and overweight are defined as growth of extra or abnormal fat leading to a high risk to an individual's health, which can be measured by using body mass index (BMI) as a baseline. A BMI of over 30 is considered as obese and a BMI of over 25 is overweight. Obesity is a high risk factor to various medical diseases such as diabetes, heart diseases and cancer.

Increasing Cases of Obese and Overweight Population to Trigger the Growth of the Obesity Drugs Market

Obesity is one of the key contributors to a wide number of non-communicable diseases which includes heart diseases, stroke and diabetes. World Obesity Atlas 2022 forecasted the growth of global obese population to be 16.1% in 2025 accounting for nearly 892 million people which will further reach to 1,025 million by 2030 with a growth rate of 17.5% in 2030. The regional obesity burden as estimated by World Obesity Atlas 2022 are listed below:-

• 1 in every 13 men and 1 in every 5 women are set to be obese by 2030 in Africa, equating to approximately 27 million men and 74 million women by 2030.
• In Americas, by 2030, growth of obesity in males is projected to be 34.41% as compared to 39.72% in females, accounting for 298 million people.

Growth Of Drug Candidates by Market Companies to enhance the Market Sales

There are many obesity drug candidates in clinical development and top market players are focusing on developing innovative medications with multiple benefits. All leading market players have invested significantly in their R&D activities to develop novel drug molecules and capture a large market share in the obesity drugs market.

Irrespective of the primary challenges such as severe side-effects associated with the weight management medicines such as nausea and diarrhea and shortage of combination therapy, the obesity drugs market has a good potential to grow at a lucrative rate and is set to gain a consistent momentum in the upcoming years.

Competitive Landscape Analysis: Obesity Drugs Market

The global obesity drugs market is marked by the presence of top market players such as below:-

• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (US)
• Altimmune (US)
• Amgen Inc. (US)
• Boehringer Ingelheim (Germany)
• Innovent Biologics, Inc. (China)
• AstraZeneca plc (UK)
• Pfizer Inc. (US)

Get Detailed Insights on Obesity Drugs Market Report with TOC @ https://meditechinsights.com/global-obesity-drugs-market/